1. Legal requirement: Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol
Management of serious breaches of clinical trials authorised in the Europe Union (EU)/ European Economic Area (EEA) is defined by Regulation (EU) No 536/2014, which states in Article 52:
“1. The sponsor shall notify the Member States concerned about a serious breach of this Regulation or of the version of the protocol applicable at the time of the breach through the EU portal without undue delay but not later than seven days of becoming aware of that breach.
2. For the purposes of this Article, a ‘serious breach’ means a breach likely to affect to a significant degree the safety and rights of a subject or the reliability and robustness of the data generated in the clinical trial.”
© European Medicines Agency, 2021
Clinical Research News
Upcoming Clinical Research Training and Conferences
-
on demandACROSS Global Training AcademyOnline
-
29 September 2023 – 02 October 2024SCDM (Society of Clinical Data Management)United States
-
21 – 23 May 2024InformaBelgium
-
03 – 04 June 2024The Society for Clinical Research Sites (SCRS)United States
-
16 – 17 July 2024The Society for Clinical Research Sites (SCRS)Australia
-
27 September – 29 October 2024The Society for Clinical Research Sites (SCRS)United States
다가오는 임상 시험
-
Hansoh BioMedical R&D Company아직 모집하지 않음
-
Istanbul Bilgi University아직 모집하지 않음균형 | 점프 성능 | 민첩성 테스트
-
Hospital San Carlos, MadridAsociación de Afectados Por Tumores Cerebrales en España (ASATE)모병교모세포종 | 교모세포종 다형 | 방사선 요법; 합병증 | 교모세포종, IDH-야생형 | 암 뇌스페인
-
AlaMab Therapeutics (Shanghai) Inc.아직 모집하지 않음뼈에만 전이된 진행성 고형 종양
-
Fondazione Policlinico Universitario Agostino Gemelli...아직 모집하지 않음자궁 경부암 | 자궁경부암
-
Istituto per la Ricerca e l'Innovazione BiomedicaMessina, Italy모병